| Similar Articles |
|---|
 |
The Motley Fool
September 26, 2008
Brian Lawler |
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages.   |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
The Motley Fool
January 24, 2008
Brian Lawler |
Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
June 13, 2007
Brian Lawler |
Tracking Vertex The pharmaceutical updates investors on the progress of its lead compound. |
The Motley Fool
April 23, 2008
Brian Lawler |
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. |
The Motley Fool
July 25, 2007
Brian Lawler |
Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report. |
The Motley Fool
May 23, 2008
Brian Lawler |
Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay. |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
The Motley Fool
March 4, 2009
Brian Orelli |
Vertex Combines to Keep From Being Ground Up Vertex Pharmaceuticals announces that it is buying ViroChem Pharma, getting two early stage hepatitis C compounds in the deal. |
The Motley Fool
April 1, 2008
Brian Lawler |
Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier. |
The Motley Fool
August 4, 2010
Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool
April 25, 2008
Brian Lawler |
Vertex Silences the Critics New clinical study data bodes well for Vertex Pharmaceuticals' lead drug. |
The Motley Fool
July 10, 2009
Brian Orelli |
Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
January 28, 2008
Brian Lawler |
Vertex Has a Lot to Prove Vertex Pharmaceuticals announces that final results from its upcoming phase 3 trials wouldn't be ready until the middle of 2010, a far cry from the filing in 2008 that Vertex was previously forecasting. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool
August 4, 2010
Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Little Funding for Pharmasset Development-stage drugmaker Pharmasset may be on to something with its hepatitis C compounds. |
The Motley Fool
August 30, 2007
Brian Lawler |
Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
June 27, 2008
Brian Lawler |
Difficult Obstacles for SciClone With all the new technologies and discoveries, some drugmakers are undoubtedly going to be left in the dust. SciClone Pharmaceuticals, with its lead drug Zadaxin, might be one such drugmaker. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
September 24, 2008
Brian Lawler |
One Share Offering Too Many for Vertex? Developmental drugmaker Vertex raises cash again by diluting itself. |
The Motley Fool
July 24, 2007
Brian Lawler |
Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance. |
The Motley Fool
November 6, 2007
Brian Lawler |
No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns? |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
October 30, 2006
Brian Lawler |
Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data. |
The Motley Fool
March 27, 2007 |
Fast Pitch: Vertex Pharmaceuticals 2007 is expected to be a very eventful year for the pharmaceutical, as it will furnish some important clinical trial results for its investigational drugs. Investors, take note. |
The Motley Fool
December 14, 2006
Brian Lawler |
Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
April 29, 2008
Brian Lawler |
So Pharmasset, So Good Early data hints at a promising hepatitis C treatment. |
The Motley Fool
May 12, 2008
Brian Lawler |
Hep C Drugs Slug It Out Does Vertex's telaprevir really trump Schering's boceprevir? |
The Motley Fool
October 7, 2010
Brian Orelli |
Asset Sold, Questions Begin Why did InterMune sells its stake in danoprevir? |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool
April 3, 2008
Brian Lawler |
Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
July 27, 2011
Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
December 9, 2008
Brian Orelli |
Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences. |
The Motley Fool
March 17, 2008
Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool
October 30, 2006
Brian Lawler |
InterMune Plays "Let's Make a Deal" The biopharmaceutical 's deal with Roche could mean stiff competition for rival Vertex. Investors, take note. |
The Motley Fool
June 14, 2011
Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
July 29, 2011
Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. |
